The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis.

Hdl Handle:
http://hdl.handle.net/10147/200309
Title:
The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis.
Authors:
Neff, K; Stack, J; Harney, S; Henry, M
Affiliation:
Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland. karljneff@gmail.com
Citation:
The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis. 2010, 65 (6):545-6 Thorax
Journal:
Thorax
Issue Date:
Jun-2010
URI:
http://hdl.handle.net/10147/200309
DOI:
10.1136/thx.2009.128710
PubMed ID:
20522855
Abstract:
A case of debilitating cavitating lung disease associated with rheumatoid arthritis and bronchocentric granulomatosis, which failed to respond to conventional medical or surgical treatment, is described. The patient was treated over 10 years with steroids, antimicrobial agents, disease-modifying antirheumatoid drugs and surgery. Lung function continued to decline and the patient presented for admission with recurrent pneumonia. Abatacept was initiated to modify the underlying immunopathology. Following 12 months of treatment with abatacept the patient has demonstrable improvement in lung function and lung anatomy, and has not presented to hospital with pneumonia. She has tolerated the treatment without complication. The use of abatacept has stabilised the lung disease in this case in the medium term and prevented readmission to hospital. These results suggest a larger role for abatacept in those with such disease in the future and may warrant further investigation.
Item Type:
Article
Language:
en
Description:
A case of debilitating cavitating lung disease associated with rheumatoid arthritis and bronchocentric granulomatosis, which failed to respond to conventional medical or surgical treatment, is described. The patient was treated over 10 years with steroids, antimicrobial agents, disease-modifying antirheumatoid drugs and surgery. Lung function continued to decline and the patient presented for admission with recurrent pneumonia. Abatacept was initiated to modify the underlying immunopathology. Following 12 months of treatment with abatacept the patient has demonstrable improvement in lung function and lung anatomy, and has not presented to hospital with pneumonia. She has tolerated the treatment without complication. The use of abatacept has stabilised the lung disease in this case in the medium term and prevented readmission to hospital. These results suggest a larger role for abatacept in those with such disease in the future and may warrant further investigation.
MeSH:
Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Granuloma; Humans; Immunoconjugates; Lung Diseases; Opportunistic Infections; Pulmonary Aspergillosis
ISSN:
1468-3296

Full metadata record

DC FieldValue Language
dc.contributor.authorNeff, Ken
dc.contributor.authorStack, Jen
dc.contributor.authorHarney, Sen
dc.contributor.authorHenry, Men
dc.date.accessioned2012-01-05T14:03:13Z-
dc.date.available2012-01-05T14:03:13Z-
dc.date.issued2010-06-
dc.identifier.citationThe use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis. 2010, 65 (6):545-6 Thoraxen
dc.identifier.issn1468-3296-
dc.identifier.pmid20522855-
dc.identifier.doi10.1136/thx.2009.128710-
dc.identifier.urihttp://hdl.handle.net/10147/200309-
dc.descriptionA case of debilitating cavitating lung disease associated with rheumatoid arthritis and bronchocentric granulomatosis, which failed to respond to conventional medical or surgical treatment, is described. The patient was treated over 10 years with steroids, antimicrobial agents, disease-modifying antirheumatoid drugs and surgery. Lung function continued to decline and the patient presented for admission with recurrent pneumonia. Abatacept was initiated to modify the underlying immunopathology. Following 12 months of treatment with abatacept the patient has demonstrable improvement in lung function and lung anatomy, and has not presented to hospital with pneumonia. She has tolerated the treatment without complication. The use of abatacept has stabilised the lung disease in this case in the medium term and prevented readmission to hospital. These results suggest a larger role for abatacept in those with such disease in the future and may warrant further investigation.en
dc.description.abstractA case of debilitating cavitating lung disease associated with rheumatoid arthritis and bronchocentric granulomatosis, which failed to respond to conventional medical or surgical treatment, is described. The patient was treated over 10 years with steroids, antimicrobial agents, disease-modifying antirheumatoid drugs and surgery. Lung function continued to decline and the patient presented for admission with recurrent pneumonia. Abatacept was initiated to modify the underlying immunopathology. Following 12 months of treatment with abatacept the patient has demonstrable improvement in lung function and lung anatomy, and has not presented to hospital with pneumonia. She has tolerated the treatment without complication. The use of abatacept has stabilised the lung disease in this case in the medium term and prevented readmission to hospital. These results suggest a larger role for abatacept in those with such disease in the future and may warrant further investigation.-
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAntirheumatic Agents-
dc.subject.meshArthritis, Rheumatoid-
dc.subject.meshFemale-
dc.subject.meshGranuloma-
dc.subject.meshHumans-
dc.subject.meshImmunoconjugates-
dc.subject.meshLung Diseases-
dc.subject.meshOpportunistic Infections-
dc.subject.meshPulmonary Aspergillosis-
dc.titleThe use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Respiratory Medicine, Cork University Hospital, Cork, Ireland. karljneff@gmail.comen
dc.identifier.journalThoraxen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.